Top

Graefe's Archive for Clinical and Experimental Ophthalmology

Published in:

01-04-2018 | Retinal Disorders

Mortality associated with bevacizumab intravitreal injections in age-related macular degeneration patients after acute myocardial infarct: a retrospective population-based survival analysis

Authors: Joel Hanhart, Doron S. Comaneshter, Yossi Freier-Dror, Shlomo Vinker

Published in: Graefe's Archive for Clinical and Experimental Ophthalmology | Issue 4/2018

Abstract

Background

Intraocular injections of antivascular endothelial growth factor (VEGF) agents are currently the main therapy in age-related macular degeneration (AMD). The safety of bevacizumab, an anti-VEGF compound frequently delivered off label, is debated, particularly for high-group risks. We aim to analyze the mortality associated with intravitreal injections of bevacizumab for AMD in patients previously diagnosed with acute myocardial infarct (MI).

Methods

In a national database, we identified bevacizumab-treated AMD patients with a diagnosis of MI prior to their first bevacizumab injection, delivered between September 2008 and October 2014 (n = 2100). We then generated sub-groups of patients treated within 3 months (n = 11), 6 months (n = 24), 12 months (n = 52), and 24 months (n = 124) after MI. Those patients were compared to age- and gender-matched members that had a MI at the same time and had never been exposed to anti-VEGF. Survival analysis was performed using propensity score-adjusted Cox regression.

Results

Bevacizumab-treated patients were slightly and insignificantly older than controls (mean age 83.25 vs 83.19 year, P = .75). Gender distribution was similar. In a Cox regression adjusted with propensity score, the following differences in mortality were found: within 3 months between MI and initiation of bevacizumab treatment, OR = 6.22 (95% C.I 1.08–35.97, P < .05); within 6 months, OR = 2.37 (95% C.I 0.93–6.02, P = .071); within 12 months, OR = 3.00 (95% C.I 1.44–6.28, P < .01); within 24 months after MI, OR = 2.24 (95% C.I 1.35–3.70, P < .01); and MI any time prior to first bevacizumab injection, OR = 1.71 (95% C.I 1.53–1.92, P < .001).

Conclusions

We report increased mortality associated with the use of intravitreal bevacizumab in AMD patients after MI, compared to age- and gender-matched post-MI patients with no exposure to any anti-VEGF agent. Caution should be taken while offering bevacizumab to AMD patients after MI.

Ellis LM (2005) Bevacizumab. Nat Rev Drug Discov Suppl:S8–S9CrossRefPubMed

Avery RL, Pieramici DJ, Rabena MD, Castellarin AA, Nasir MA, Giust MJ (2006) Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology 113:363–372.e365. https://doi.org/10.1016/j.ophtha.2005.11.019 CrossRefPubMed

Michels S, Rosenfeld PJ, Puliafito CA, Marcus EN, Venkatraman AS (2005) Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration twelve-week results of an uncontrolled open-label clinical study. Ophthalmology 112:1035–1047. https://doi.org/10.1016/j.ophtha.2005.02.007 CrossRefPubMed

Avery RL (2014) What is the evidence for systemic effects of intravitreal anti-VEGF agents, and should we be concerned? Br J Ophthalmol 98(Suppl 1):i7–10. https://doi.org/10.1136/bjophthalmol-2013-303844 CrossRefPubMed

Semeraro F, Morescalchi F, Duse S, Gambicorti E, Cancarini A, Costagliola C (2015) Pharmacokinetic and pharmacodynamic properties of anti-VEGF drugs after intravitreal injection. Curr Drug Metab 16:572–584CrossRefPubMed

Avery RL, Castellarin AA, Steinle NC, Dhoot DS, Pieramici DJ, See R, Couvillion S, Nasir MA, Rabena MD, Le K, Maia M, Visich JE (2014) Systemic pharmacokinetics following intravitreal injections of ranibizumab, bevacizumab or aflibercept in patients with neovascular AMD. Br J Ophthalmol 98:1636–1641. https://doi.org/10.1136/bjophthalmol-2014-305252 CrossRefPubMedPubMedCentral

Zehetner C, Kirchmair R, Huber S, Kralinger MT, Kieselbach GF (2013) Plasma levels of vascular endothelial growth factor before and after intravitreal injection of bevacizumab, ranibizumab and pegaptanib in patients with age-related macular degeneration, and in patients with diabetic macular oedema. Br J Ophthalmol 97:454–459. https://doi.org/10.1136/bjophthalmol-2012-302451 CrossRefPubMed

Matsuyama K, Ogata N, Matsuoka M, Wada M, Takahashi K, Nishimura T (2010) Plasma levels of vascular endothelial growth factor and pigment epithelium-derived factor before and after intravitreal injection of bevacizumab. Br J Ophthalmol 94:1215–1218. https://doi.org/10.1136/bjo.2008.156810 CrossRefPubMed

Bakbak B, Ozturk BT, Gonul S, Yilmaz M, Gedik S (2013) Comparison of the effect of unilateral intravitreal bevacizumab and ranibizumab injection on diabetic macular edema of the fellow eye. J Ocul Pharmacol Ther 29:728–732. https://doi.org/10.1089/jop.2013.0049 CrossRefPubMed

10.

Brito IA, Zacharias LC, Pimentel SL (2015) Fellow eye macular edema improvement after intravitreal bevacizumab for radiation retinopathy. Case Rep Ophthalmol Med 2015:516921. https://doi.org/10.1155/2015/516921 PubMedPubMedCentral

11.

Hanhart J, Tiosano L, Averbukh E, Banin E, Hemo I, Chowers I (2014) Fellow eye effect of unilateral intravitreal bevacizumab injection in eyes with diabetic macular edema. Eye (London, England) 28:646–653. https://doi.org/10.1038/eye.2014.94 CrossRef

12.

Hosseini H, Lotfi M, Esfahani MH, Nassiri N, Khalili MR, Razeghinejad MR, Nouri-Mahdavi K (2012) Effect of intravitreal bevacizumab on retrobulbar blood flow in injected and uninjected fellow eyes of patients with neovascular age-related macular degeneration. Retina (Philadelphia, Pa) 32:967–971. https://doi.org/10.1097/IAE.0b013e31822c28d6 CrossRef

13.

Karaca C, Oner AO, Mirza E, Polat OA, Sahiner M (2013) Bilateral effect of unilateral bevacizumab injection in retinopathy of prematurity. JAMA Ophthalmol 131:1099–1101. https://doi.org/10.1001/jamaophthalmol.2013.400 CrossRefPubMed

14.

Lim LS, Cheung CM, Mitchell P, Wong TY (2011) Emerging evidence concerning systemic safety of anti-VEGF agents—should ophthalmologists be concerned? Am J Ophthalmol 152:329–331. https://doi.org/10.1016/j.ajo.2011.05.040 CrossRefPubMed

15.

Tunon J, Ruiz-Moreno JM, Martin-Ventura JL, Blanco-Colio LM, Lorenzo O, Egido J (2009) Cardiovascular risk and antiangiogenic therapy for age-related macular degeneration. Surv Ophthalmol 54:339–348. https://doi.org/10.1016/j.survophthal.2009.02.003 CrossRefPubMed

16.

Scappaticci FA, Skillings JR, Holden SN, Gerber HP, Miller K, Kabbinavar F, Bergsland E, Ngai J, Holmgren E, Wang J, Hurwitz H (2007) Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. J Natl Cancer Inst 99:1232–1239. https://doi.org/10.1093/jnci/djm086 CrossRefPubMed

17.

Chen XL, Lei YH, Liu CF, Yang QF, Zuo PY, Liu CY, Chen CZ, Liu YW (2013) Angiogenesis inhibitor bevacizumab increases the risk of ischemic heart disease associated with chemotherapy: a meta-analysis. PLoS One 8:e66721. https://doi.org/10.1371/journal.pone.0066721 CrossRefPubMedPubMedCentral

18.

Monsuez JJ, Charniot JC, Vignat N, Artigou JY (2010) Cardiac side-effects of cancer chemotherapy. Int J Cardiol 144:3–15. https://doi.org/10.1016/j.ijcard.2010.03.003 CrossRefPubMed

19.

Ranpura V, Hapani S, Chuang J, Wu S (2010) Risk of cardiac ischemia and arterial thromboembolic events with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis of randomized controlled trials. Acta Oncol (Stockholm, Sweden) 49:287–297. https://doi.org/10.3109/02841860903524396 CrossRef

20.

Avery RL, Gordon GM (2016) Systemic safety of prolonged monthly anti-vascular endothelial growth factor therapy for diabetic macular edema: a systematic review and meta-analysis. JAMA Ophthalmol 134:21–29. https://doi.org/10.1001/jamaophthalmol.2015.4070 CrossRefPubMed

21.

Hirai FE, Knudtson MD, Klein BE, Klein R (2008) Clinically significant macular edema and survival in type 1 and type 2 diabetes. Am J Ophthalmol 145:700–706. https://doi.org/10.1016/j.ajo.2007.11.019 CrossRefPubMedPubMedCentral

22.

Kemp A, Preen DB, Morlet N, Clark A, McAllister IL, Briffa T, Sanfilippo FM, Ng JQ, McKnight C, Reynolds W, Gilles MC (2013) Myocardial infarction after intravitreal vascular endothelial growth factor inhibitors: a whole population study. Retina (Philadelphia, Pa) 33:920–927. https://doi.org/10.1097/IAE.0b013e318276e07b CrossRef

23.

Rich RM, Rosenfeld PJ, Puliafito CA, Dubovy SR, Davis JL, Flynn HW Jr, Gonzalez S, Feuer WJ, Lin RC, Lalwani GA, Nguyen JK, Kumar G (2006) Short-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Retina (Philadelphia, Pa) 26:495–511. https://doi.org/10.1097/01.iae.0000225766.75009.3a CrossRef

24.

Lazic R, Gabric N (2007) Intravitreally administered bevacizumab (Avastin) in minimally classic and occult choroidal neovascularization secondary to age-related macular degeneration. Graefe's Arch Clin Exp Ophthalmol = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie 245:68–73. https://doi.org/10.1007/s00417-006-0466-4 CrossRef

25.

Lazic R, Gabric N (2007) Verteporfin therapy and intravitreal bevacizumab combined and alone in choroidal neovascularization due to age-related macular degeneration. Ophthalmology 114:1179–1185. https://doi.org/10.1016/j.ophtha.2007.03.006 CrossRefPubMed

26.

Fung AE, Rosenfeld PJ, Reichel E (2006) The international intravitreal bevacizumab safety survey: using the internet to assess drug safety worldwide. Br J Ophthalmol 90:1344–1349. https://doi.org/10.1136/bjo.2006.099598 CrossRefPubMedPubMedCentral

27.

Martin DF, Maguire MG, Ying GS, Grunwald JE, Fine SL, Jaffe GJ (2011) Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med 364:1897–1908. https://doi.org/10.1056/NEJMoa1102673 CrossRefPubMed

28.

Moja L, Lucenteforte E, Kwag KH, Bertele V, Campomori A, Chakravarthy U, D'Amico R, Dickersin K, Kodjikian L, Lindsley K, Loke Y, Maguire M, Martin DF, Mugelli A, Muhlbauer B, Puntmann I, Reeves B, Rogers C, Schmucker C, Subramanian ML, Virgili G (2014) Systemic safety of bevacizumab versus ranibizumab for neovascular age-related macular degeneration. Cochrane Database Syst Rev 9:Cd011230. https://doi.org/10.1002/14651858.CD011230.pub2 PubMedCentral

29.

Biswas P, Sengupta S, Choudhary R, Home S, Paul A, Sinha S (2011) Comparing ranibizumab with bevacizumab. Ophthalmology 118:600–600.e602. https://doi.org/10.1016/j.ophtha.2010.10.027 CrossRefPubMed

30.

Subramanian ML, Abedi G, Ness S, Ahmed E, Fenberg M, Daly MK, Houranieh A, Feinberg EB (2010) Bevacizumab vs ranibizumab for age-related macular degeneration: 1-year outcomes of a prospective, double-masked randomised clinical trial. Eye (London, England) 24:1708–1715. https://doi.org/10.1038/eye.2010.147 CrossRef

31.

Krebs I, Schmetterer L, Boltz A, Told R, Vecsei-Marlovits V, Egger S, Schonherr U, Haas A, Ansari-Shahrezaei S, Binder S (2013) A randomised double-masked trial comparing the visual outcome after treatment with ranibizumab or bevacizumab in patients with neovascular age-related macular degeneration. Br J Ophthalmol 97:266–271. https://doi.org/10.1136/bjophthalmol-2012-302391 CrossRefPubMed

32.

Kodjikian L, Souied EH, Mimoun G, Mauget-Faysse M, Behar-Cohen F, Decullier E, Huot L, Aulagner G (2013) Ranibizumab versus bevacizumab for neovascular age-related macular degeneration: results from the GEFAL Noninferiority Randomized Trial. Ophthalmology 120:2300–2309. https://doi.org/10.1016/j.ophtha.2013.06.020 CrossRefPubMed

33.

Chakravarthy U, Harding SP, Rogers CA, Downes SM, Lotery AJ, Culliford LA, Reeves BC (2013) Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial. Lancet (London, England) 382:1258–1267. https://doi.org/10.1016/s0140-6736(13)61501-9 CrossRef

34.

Martin DF, Maguire MG, Fine SL, Ying GS, Jaffe GJ, Grunwald JE, Toth C, Redford M, Ferris FL 3rd (2012) Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology 119:1388–1398. https://doi.org/10.1016/j.ophtha.2012.03.053 CrossRefPubMedPubMedCentral

35.

Mikacic I, Bosnar D (2016) Intravitreal bevacizumab and cardiovascular risk in patients with age-related macular degeneration: systematic review and meta-analysis of randomized controlled trials and observational studies. Drug Saf. https://doi.org/10.1007/s40264-016-0408-y

36.

Rennert G, Peterburg Y (2001) Prevalence of selected chronic diseases in Israel. Isr Med Assoc J: IMAJ 3:404–408PubMed

37.

Ikram MK, Mitchell P, Klein R, Sharrett AR, Couper DJ, Wong TY (2012) Age-related macular degeneration and long-term risk of stroke subtypes. Stroke 43:1681–1683. https://doi.org/10.1161/strokeaha.112.654632 CrossRefPubMedPubMedCentral

38.

Klein R, Peto T, Bird A, Vannewkirk MR (2004) The epidemiology of age-related macular degeneration. Am J Ophthalmol 137:486–495. https://doi.org/10.1016/j.ajo.2003.11.069 CrossRefPubMed

39.

Boberg-Ans G, Henning V, Villumsen J, la Cour M (2006) Longterm incidence of rhegmatogenous retinal detachment and survival in a defined population undergoing standardized phacoemulsification surgery. Acta Ophthalmol Scand 84:613–618. https://doi.org/10.1111/j.1600-0420.2006.00719.x CrossRefPubMed

40.

Hicks KA, Tcheng JE, Bozkurt B, Chaitman BR, Cutlip DE, Farb A, Fonarow GC, Jacobs JP, Jaff MR, Lichtman JH, Limacher MC, Mahaffey KW, Mehran R, Nissen SE, Smith EE, Targum SL (2015) 2014 ACC/AHA key data elements and definitions for cardiovascular endpoint events in clinical trials: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Data Standards (Writing Committee to Develop Cardiovascular Endpoints Data Standards). Circulation 132:302–361. https://doi.org/10.1161/cir.0000000000000156 CrossRefPubMed

41.

American Psychiatric Association (1994) Diagnostic and statistical manual of mental disorders : DSM-IV. American Psychiatric Press Inc, Washington DC

42.

Grinnon ST, Miller K, Marler JR, Lu Y, Stout A, Odenkirchen J, Kunitz S (2012) National Institute of Neurological Disorders and Stroke Common Data Element Project—approach and methods. Clin Trials (London, England) 9:322–329. https://doi.org/10.1177/1740774512438980 CrossRef

43.

Cox DR (1972) Regression models and life-tables. J R Stat Soc Ser B Methodol 34:187–220

44.

Austin PC (2011) An introduction to propensity score methods for reducing the effects of confounding in observational studies. Multivar Behav Res 46:399–424. https://doi.org/10.1080/00273171.2011.568786 CrossRef

45.

Bronnum-Hansen H, Jorgensen T, Davidsen M, Madsen M, Osler M, Gerdes LU, Schroll M (2001) Survival and cause of death after myocardial infarction: the Danish MONICA study. J Clin Epidemiol 54:1244–1250CrossRefPubMed

46.

Crafts TD, Jensen AR, Blocher-Smith EC, Markel TA (2015) Vascular endothelial growth factor: therapeutic possibilities and challenges for the treatment of ischemia. Cytokine 71:385–393. https://doi.org/10.1016/j.cyto.2014.08.005 CrossRefPubMed

47.

Hojo Y, Ikeda U, Zhu Y, Okada M, Ueno S, Arakawa H, Fujikawa H, Katsuki T, Shimada K (2000) Expression of vascular endothelial growth factor in patients with acute myocardial infarction. J Am Coll Cardiol 35:968–973CrossRefPubMed

48.

Ogawa H, Suefuji H, Soejima H, Nishiyama K, Misumi K, Takazoe K, Miyamoto S, Kajiwara I, Sumida H, Sakamoto T, Yoshimura M, Kugiyama K, Yasue H, Matsuo K (2000) Increased blood vascular endothelial growth factor levels in patients with acute myocardial infarction. Cardiology 93:93–99CrossRefPubMed

49.

Gopinath B, Liew G, Burlutsky G, Mitchell P (2016) Age-related macular degeneration and risk of total and cause-specific mortality over 15 years. Maturitas 84:63–67. https://doi.org/10.1016/j.maturitas.2015.11.001 CrossRefPubMed

50.

Golan S, Shalev V, Goldstein M, Treister G, Chodick G, Loewenstein A (2011) The rate of myocardial infarction events among patients with age-related macular degeneration: a population-based study. Graefe’s Arch Clin Exp Ophthalmol = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie 249:179–182. https://doi.org/10.1007/s00417-010-1489-4 CrossRef

51.

Wong TY, Tikellis G, Sun C, Klein R, Couper DJ, Sharrett AR (2007) Age-related macular degeneration and risk of coronary heart disease: the Atherosclerosis Risk in Communities Study. Ophthalmology 114:86–91. https://doi.org/10.1016/j.ophtha.2006.06.039 CrossRefPubMed

52.

Liew G, Wang JJ, Wong TY (2007) Macular degeneration and heart disease. Ophthalmology 114:1793–1793.e1791. https://doi.org/10.1016/j.ophtha.2007.04.036 CrossRefPubMed

53.

Bandello F, Lafuma A, Berdeaux G (2007) Public health impact of neovascular age-related macular degeneration treatments extrapolated from visual acuity. Invest Ophthalmol Vis Sci 48:96–103. https://doi.org/10.1167/iovs.06-0283 CrossRefPubMed

54.

Arevalo JF, Lasave AF, Wu L, Acon D, Berrocal MH, Diaz-Llopis M, Gallego-Pinazo R, Serrano MA, Alezzandrini AA, Rojas S, Maia M, Lujan S (2015) Intravitreal bevacizumab for choroidal neovascularization in age-related macular degeneration: 5-year results of the Pan-American Collaborative Retina Study Group. Retina (Philadelphia, Pa). https://doi.org/10.1097/iae.0000000000000827

55.

Berg K, Pedersen TR, Sandvik L, Bragadottir R (2015) Comparison of ranibizumab and bevacizumab for neovascular age-related macular degeneration according to LUCAS treat-and-extend protocol. Ophthalmology 122:146–152. https://doi.org/10.1016/j.ophtha.2014.07.041 CrossRefPubMed

56.

Solomon SD, Lindsley KB, Krzystolik MG, Vedula SS, Hawkins BS (2016) Intravitreal bevacizumab versus ranibizumab for treatment of neovascular age-related macular degeneration: findings from a Cochrane Systematic Review. Ophthalmology 123:70–77.e71. https://doi.org/10.1016/j.ophtha.2015.09.002 CrossRefPubMed

57.

Ng WY, Tan GS, Ong PG, Cheng CY, Cheung CY, Wong DW, Mathur R, Chow KY, Wong TY, Cheung GC (2015) Incidence of myocardial infarction, stroke, and death in patients with age-related macular degeneration treated with intravitreal anti-vascular endothelial growth factor therapy. Am J Ophthalmol 159:557–564.e551. https://doi.org/10.1016/j.ajo.2014.12.005 CrossRefPubMed

58.

Etminan M, Maberley DA, Babiuk DW, Carleton BC (2016) Risk of myocardial infarction and stroke with single or repeated doses of intravitreal bevacizumab in age-related macular degeneration. Am J Ophthalmol 163:53–58. https://doi.org/10.1016/j.ajo.2015.11.030 CrossRefPubMed

59.

Hanhart J, Vinker S (2016) Risk of myocardial infarction and stroke with single or repeated doses of intravitreal bevacizumab in age-related macular degeneration. Am J Ophthalmol. https://doi.org/10.1016/j.ajo.2016.03.027

60.

Gottlieb SS (1997) Dead is dead—artificial definitions are no substitute. Lancet (London, England) 349:662–663. https://doi.org/10.1016/s0140-6736(97)22010-6 CrossRef

61.

Fung AE, Apte RS, Nguyen-Khoa BA, Goehring EL, Werther W, Jones JK (2009) Myocardial infarction and cerebrovascular accident in patients with diabetic macular edema. Invest Ophthalmol Vis Sci 50:4423–4423

Title: Mortality associated with bevacizumab intravitreal injections in age-related macular degeneration patients after acute myocardial infarct: a retrospective population-based survival analysis
Authors: Joel Hanhart
Doron S. Comaneshter
Yossi Freier-Dror
Shlomo Vinker
Publication date: 01-04-2018
Publisher: Springer Berlin Heidelberg
Published in: Graefe's Archive for Clinical and Experimental Ophthalmology / Issue 4/2018
Print ISSN: 0721-832X
Electronic ISSN: 1435-702X
DOI: https://doi.org/10.1007/s00417-018-3917-9

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Mortality associated with bevacizumab intravitreal injections in age-related macular degeneration patients after acute myocardial infarct: a retrospective population-based survival analysis

Abstract

Background

Methods

Results

Conclusions

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 4/2018

Trends in treatment strategies for suspected bacterial endophthalmitis

Comparison of conventional color fundus photography and multicolor imaging in choroidal or retinal lesions

Floating flap of internal limiting membrane in myopic macular hole surgery

Normative measurements of inferior oblique muscle thickness in Japanese by magnetic resonance imaging using a new technique

Colour discrimination ellipses in choroideremia

The XEN45 Gel Stent as a minimally invasive procedure in glaucoma surgery: success rates, risk profile, and rates of re-surgery after 261 surgeries